Preventing COVID-19 in Healthcare Workers With HCQ: A RCT

• Status: Withdrawn
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Healthcare workers (HCW) at risk of Covid-19 will have baseline serology for SARS-CoV-2 to see if they are already immune to Covid-19. HCW will get baseline assessment and if meeting inclusion criteria and no exclusion criteria they will be randomized in a 2:1 ratio to hydroxychloroquine or Vitamin C on a weekly basis for three months. Subjects will complete daily diary of symptoms and temperature, and will have repeat SARS-CoV-2 serology at 6 weeks and 3 months to determine seroconversion.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stony Brook University
• Treatments: Ascorbic Acid; Hydroxychloroquine

Criteria

Inclusion Criteria:

• Healthcare worker at risk of Covid-19

Exclusion Criteria:

• Known hypersensitivity or allergic reactions to 4-aminoquinoline compounds or its ingredients.

• Current, or history of, ocular macular disease or retinal damage.

• Current, or history of, subnormal glomerular filtration.

• Current use of tamoxifen citrate.

• Current, or history of, cardiomyopathy, atrial, nodal, or ventricular arrhythmias, torsades de pointes, conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy.

• Subjects taking other drugs that have the potential to prolong QT interval if taken with HCQ.